<DOC>
	<DOCNO>NCT01383343</DOCNO>
	<brief_summary>This phase I trial study side effect best dose sorafenib tosylate give together bevacizumab , irinotecan hydrochloride , leucovorin calcium , fluorouracil treat patient colorectal cancer spread part body . Drugs use chemotherapy , irinotecan hydrochloride , leucovorin calcium , fluorouracil , work different way stop growth tumor cell , either kill cell , stop dividing , stop spread . Sorafenib tosylate may stop growth tumor cell block enzymes need cell growth . Monoclonal antibody , bevacizumab , may interfere ability tumor cell grow spread . Sorafenib tosylate bevacizumab may also block tumor growth different way target certain cell . Giving sorafenib tosylate bevacizumab together combination chemotherapy may better treatment colorectal cancer .</brief_summary>
	<brief_title>Sorafenib Tosylate , Bevacizumab , Irinotecan Hydrochloride , Leucovorin Calcium , Fluorouracil Treating Patients With Metastatic Colorectal Cancer</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine maximally tolerate dose combination irinotecan hydrochloride , leucovorin calcium , fluorouracil ( FOLFIRI ) plus sorafenib ( sorafenib tosylate ) plus bevacizumab . SECONDARY OBJECTIVES : I . To assess safety FOLFIRI plus sorafenib plus bevacizumab . II . To assess feasibility propose combination . III . To evaluate response rate identify activity propose combination . OUTLINE : This dose-escalation study sorafenib tosylate follow cohort study . ( Cohort study cancel March 25 , 2014 ) Patients receive irinotecan hydrochloride intravenously ( IV ) 90 minute day 1 , leucovorin calcium IV 2 hour day 1 , fluorouracil IV continuously 46 hour day 1-2 , bevacizumab IV 30-90 minute day 1 , sorafenib tosylate orally ( PO ) ( QD ) twice daily ( BID ) day 3-6 10-13* . Courses repeat every 14 day absence disease progression unacceptable toxicity . NOTE : *Patients may also receive sorafenib tosylate day 7 14 . After completion study therapy , patient follow 3 month .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Rectal Neoplasms</mesh_term>
	<mesh_term>Colonic Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<mesh_term>Leucovorin</mesh_term>
	<mesh_term>Folic Acid</mesh_term>
	<mesh_term>Endothelial Growth Factors</mesh_term>
	<mesh_term>Calcium , Dietary</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Immunoglobulin G</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<criteria>This trial intend gastrointestinal malignancy appropriate irinotecanbased therapy ; histologic proof cancer unresectable ; prior therapy receive , patient must show progressive disease prior treatment within 6 month recent therapy Measurable disease nonmeasurable disease Absolute neutrophil count ( ANC ) &gt; = 1500/uL Platelet ( PLT ) &gt; = 100,000/uL Hemoglobin ( Hgb ) &gt; = 9.0 gm/dL Total bilirubin = &lt; upper limit normal ( ULN ) Alkaline phosphatase = &lt; 3 x ULN Aspartate aminotransferase ( AST ) = &lt; 3 x ULN OR AST = &lt; 5 x ULN liver involvement International normalized ratio ( INR ) &lt; 1.5 unless patient receive anticoagulation therapy ; patient receive anticoagulation therapy agent warfarin heparin allow participate INR = &lt; 3.0 Urine protein creatinine ( UPC ) ratio &lt; 1 urine dipstick &lt; 2+ NOTE : urine protein must screen urine analysis UPC ratio dipstick ; UPC ratio &gt; = 1.0 , 24hour urine protein must obtain level &lt; 1000 mg Creatinine = &lt; 1.5 x ULN Calculated creatinine clearance must &gt; = 45 mL/min use CockcroftGault formula Eastern Cooperative Oncology Group ( ECOG ) performance status ( PS ) 0 1 Ability provide inform consent Willing return Mayo Clinic follow Life expectancy &gt; = 84 day ( 3 month ) Women childbearing potential : negative pregnancy test do = &lt; 7 day prior registration Known standard therapy patient 's disease potentially curative Note : Prior treatment irinotecan , 5fluoruracil bevacizumab allow Prior treatment sorafenib allow Inadequately control hypertension ( systolic blood pressure &gt; 150 mmHg diastolic pressure &gt; 100 mmHg antihypertensive medication ) Prior history hypertensive crisis hypertensive encephalopathy History myocardial infarction unstable angina = &lt; 6 month prior registration congestive heart failure require use ongoing maintenance therapy lifethreatening ventricular arrhythmias Heart failure New York Heart Association classification III IV Thrombolic embolic event cerebrovascular accident include transient ischemic attack = &lt; 6 month prior registration Any hemorrhage/bleeding event &gt; grade 3 = &lt; 4 week prior registration Evidence history bleed diathesis ( great normal risk bleed ) coagulopathy ( absence therapeutic anticoagulation ) ; NOTE : patient fulldose anticoagulant eligible provided patient stable dose least 2 week low molecular weight heparin warfarin INR range 23 ; aspirin dos &gt; 325 mg PO daily allow Active recent hemoptysis ( &gt; = Â½ teaspoon bright red blood per episode ) = &lt; 30 day prior registration Serious , nonhealing wound , active ulcer , untreated bone fracture ; NOTE : patient fracture secondary metastatic disease eligible appropriate radiotherapy Significant vascular disease ( e.g. , aortic aneurysm , aortic dissection ) , recent peripheral arterial thrombosis , symptomatic peripheral vascular disease = &lt; 6 month prior registration History abdominal fistula , gastrointestinal perforation , intraabdominal abscess = &lt; 6 month prior registration Major surgical procedure , open biopsy , significant traumatic injury = &lt; 28 day prior registration anticipation need major surgical procedure course study ; EXCEPTION : core biopsy minor surgical procedure , include placement vascular access device , = &lt; 7 day prior registration allow Patients take cytochrome P450 enzymeinducing antiepileptic drug = &lt; 4 week prior registration exclude ( phenytoin , carbamazepine , phenobarbital , rifampin , St. John 's wort ) Known suspect allergy hypersensitivity agent give course trial Any condition impair patient 's ability swallow whole pill Any malabsorption problem Any follow prior therapy : Chemotherapy = &lt; 14 day prior registration Immunotherapy = &lt; 28 day prior registration Radiation therapy = &lt; 28 day prior registration Radiation &gt; 25 % bone marrow Failure fully recover acute , reversible effect prior chemotherapy regardless interval since last treatment Known brain metastasis ; NOTE : patient neurological symptom must undergo compute tomography ( CT ) scan/magnetic resonance imaging ( MRI ) brain exclude brain metastasis Any following : Pregnant woman Nursing woman Men woman childbearing potential unwilling employ adequate contraception Other concurrent chemotherapy , immunotherapy , radiotherapy , ancillary therapy consider investigational ( utilized nonFood Drug Administration [ FDA ] approve indication context research investigation ) Receiving investigational agent would consider treatment primary neoplasm Comorbid systemic illness severe concurrent disease , judgment investigator , would make patient inappropriate entry study interfere significantly proper assessment safety toxicity prescribe regimens Other active malignancy = &lt; 3 year prior registration ; EXCEPTIONS : nonmelanotic skin cancer carcinomainsitu cervix ; NOTE : history prior malignancy , must receive specific treatment cancer , include hormonal therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>